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Elevation of reactive oxygen species (ROS) is both a consequence and driver of the 
upregulated metabolism and proliferation of transformed cells. The resulting increase 
in oxidative stress is postulated to saturate the cellular antioxidant machinery, leaving 
cancer cells susceptible to agents that further elevate their intracellular oxidative 
stress. Several small molecules, including the marine natural product cribrostatin 6, 
have been demonstrated to trigger apoptosis in cancer cells by increasing intracellular 
ROS. Here, we report the modular synthesis of a series of cribrostatin 6 derivatives, 
and assessment of their activity in a number of cell lines. We establish that placing a 
phenyl ring on carbon 8 of cribrostatin leads to increase potency, and observe a 
window of selectivity towards cancer cells. The mechanism of activity of this more 
potent analogue is assessed and demonstrated to induce apoptosis in cancer cells by 
increasing ROS. Our results demonstrate the potential for targeting tumors with 
molecules that enhance intracellular oxidative stress. 
 
Aerobic glycolysis is a key characteristic of cancer cells that significantly affects the 
metabolic pathways and metabolites of transformed cells. While these changes enable 
the unregulated growth and survival of cancer cells, they may also be used for selective 
chemotherapeutic targeting. One such defining change is the increased production of 
ROS and the subsequent additional oxidative stress placed on cancer cells (1), which 
is thought to be play a key role in the maintenance of the tumour phenotype (2-4). 
Adaptation to this increase in oxidative stress requires upregulation of the cellular 
antioxidant machinery, which works to maintain the reducing environment necessary 
for correct function of a variety of cellular processes (5). NADPH and glutathione are 
key antioxidants whose levels are elevated in response to increased ROS. The 
antioxidant machinery of cancer cells is thought to operate at near capacity due to 
higher basal ROS and upregulated ROS-mediated signalling, which potentially makes 
them vulnerable to agents that cause additional oxidative pressure, providing a 
mechanism by which cancer cells can be selectively targeted (6). In line with this 
hypothesis, a range of chemotherapeutics have been proposed to function by 
increasing the oxidative stress in cancer cells (7-10), and several screens aimed at 
identifying compounds that selectively inhibit the growth of transformed cells have 
converged on compounds that act to increase oxidative pressure by reducing 
glutathione levels (11-13). Compounds such as phenyl isocyanate (12), 2-
methoxyoestradiol (14), and piperlongumine (11) selectively kill cancer cells (at doses 
of 5-20 µM) by interfering with ROS homeostasis pathways.  
Cribrostatin 6 is an imidazo[5,1-a]isoquinoline isolated from the marine sponge 
Cribrochalina sp (15), which has been shown to be cytotoxic in several cancer cell lines, 
triggering apoptosis by elevating intracellular ROS (16). The mechanism of this process 
is likely to be similar to other quinones, which undergo bioreduction in cells to the 
corresponding semiquinone, which then reacts with molecular oxygen to generate 
superoxide (8). Cancer cells treated with cribrostatin 6 also showed an elevation of 
antioxidant transcripts, including heme oxygenase 1, several ferritins and proteins 
associated with glutathione synthesis (16). Although cribrostatin 6 has been shown to 
affect the viability of cancer cell lines, its selectivity for cancer cells over normal cells 
has never been demonstrated. Such selectivity is seldom explored, yet is increasingly 
seen as a critical property of compounds proposed as potential cancer therapeutics. 
Given its mechanism of action and the demonstrated susceptibility of cancer cells to 
additional oxidative stress, we sought to generate a more potent analogue of 
cribrostatin 6, with the aim of improving both the potency and cancer cell selectivity. 
 
 
Scheme 1. Synthesis of cribrostatin 6 and analogues A-K.  
 
There have been several reported total syntheses of cribrostatin 6 (17-21). We chose 
to adapt a modular route that we had developed as it facilitated the rapid incorporation 
of a variety of substituents on carbons 8 and 9 of the isoquinoline ring and was readily 
adapted to reverse the positioning of these alkyl and alkoxy residues (Scheme 1) (20). 
Thus, the brominated core, imidazo[1,5-a]pyridine 4, was prepared in three steps from 
3-bromo-2-cyanopyridine 1 as previously described (20). Contemporaneously, a series 
of cyclobutenediones 8 were prepared as surrogates for the quinone ring each bearing 
alkoxy and organyl residues at C3 and C4 respectively. Syntheses of cribrostatin 6 and 
analogues B–K were then achieved by halogen–lithium exchange of 4, addition of the 
resulting aryllithium 9 to a cyclobutenedione 8 and thermolysis of the resulting adduct 
7 with aerial oxidation. To achieve a synthesis of analogue A, in which the positions of 
the alkyl and alkoxy residues are swapped, required a subtle change of strategy. In this 
case the simple expedient of switching from organolithium intermediate 9 to 
organoytterbium ate complex 11 changed the course of nucleophilic addition in favor 
of addition to the vinylogous ester carbonyl C3 (22). Thermolysis of the resulting adduct 
10 followed by aerial oxidation then gave analogue A.  
The effect of cribrostatin 6 and analogues A–K on the viability of MCF7 breast cancer 
cells was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay (Table 1 and Supplementary Figure 1-12). The most potent molecule 
was analogue D (IC50 of 428 ± 40 nM) with a phenyl ring on C8 in place of the methyl 
residue found in the parent molecule (Figure 1A, from hereon referred to as 8PC6, for 
8-phenylcribrostatin 6). This substitution resulted in a 30% increase in potency against 
MCF7 breast cancer cells compared to cribrostatin 6 (IC50 of 628 ± 67 nM). 
 
Table 1. The effect of cribrostatin 6 and its synthetic analogues on the viability of MCF7 breast cancer 
cells. R and R’ refer to structures in Scheme 1.  
Compound R R’ IC50 (nM) 
Cribrostatin 6 OEt Me 628 ± 67 
Analogue A Me  OtBu 2064 ± 884 
Analogue B OtBu Me  1546 ± 243 
Analogue C OEt tBu 1671 ± 112 
Analogue D OEt Ph 428 ± 40 
Analogue E OEt Naphthyl 2024 ± 329 
Analogue F OEt 2,4,6-(OMe)3Ph 1692 ± 209 
Analogue G OEt 4-(Me3Si)Ph 5064 ± 2766 
Analogue H OEt 4-(Me)Ph 993 ± 160 
Analogue I OEt 4-(F3C)Ph 1661 ± 230 
Analogue J OEt 4-(Me3C)Ph 4275 ± 1358 
Analogue K OEt 4-(2-furanyl) 2393 ± 476 
 
With a more potent analogue in hand, we assessed the effect of 1 µM 8PC6 on a 
number of cancer and non-cancer cell lines from a variety of tissue types (Figure 1B). 
As a comparison, we also assessed the effect of 1 µM cribrostatin 6 in the same panel 
of cells (Figure 1). 8PC6 was more potent than cribrostatin 6 in all cases, with a greater 
effect on the viability of the cancer cell lines (reduced to 16-28%) than normal cells 
(reduced to 69-88%). The selectivity of cribrostatin 6 for the cancer cell lines in our 
panel (reduced to 36-54%) over normal cells (viability reduced to 69-87%) was less 
pronounced at this dose (Figure 1).  
 
Figure 1. Selective inhibition of cancer cell viability by cribrostatin 6 and 8PC6. A) the crystal 
structure of 8P6C (CCDC deposition code 1060587). B) The effect of 1 µM cribrostatin 6 and 8PC6 on 
the viability of a panel of cancer and non-cancer cell lines.  
 
Table 2. The effect of 8PC6 and cribrostatin 6 on the viability of a variety of cell lines 
Cell line Tissue and type 8PC6 IC50 (nM) Cribrostatin 6 IC50 (nM) 
MRC-5 Lung, normal 1845 ± 186 2231 ± 173 
CCD841 Colon, normal 1798 ± 429 2189 ± 587 
MDA-MB-231 Breast, adenocarcinoma 502 ± 76 726 ± 99 
MCF7 Breast, adenocarcinoma 428 ± 40 628 ± 67 
PANC-1 
Pancreas, epithelioid 
carcinoma 
505 ± 55 1045 ± 212 
HeLa Cervix, adenocarcinoma 418 ± 36 659 ± 51 
HCT 116 
Colon, colorectal 
carcinoma 
548 ± 69 748 ± 75 
 
The IC50 of 8PC6 was next determined by MTT assay in each of these cell lines (Table 
2, and Supplementary Figure 20-26). The IC50 of 8PC6 was found to be ca. four-fold 
higher in non-cancer cell lines (average IC50 of 1.8 µM) than that in cancer cell lines 
(average IC50 of 480 nM). In addition, 8PC6 was more potent than its parent molecule 
in every cell line (Table 2). 
 
 
Figure 2. The effect of 8PC6 on intracellular ROS, and the effect of increased intracellular ROS 
on the potency of 8PC6. A) Flow cytometric analysis of the effect of 8PC6 treatment on the cell 
population by annexin V and 7-aminoactinomycin staining and flow cytometry. For scatter plots see 
Supplementary Figure 27. B) Phase and fluorescent micrographs of MCF7 cells treated with 100 µM 
DCDFA (upper panel), and MCF7 cells dosed with 100 µM DCDFA followed by 2.5 µM 8PC6 (lower 
panel). Intracellular ROS causes DCDFA to be Fluorescent at 529 nm. C) Quantifying the increase in 
the fluorescence (at 529 nm) of MCF7 cells treated with 100 µM DCDFA and increasing doses of 8PC6. 
D) The effect of TIGAR and scrambled siRNA on TIGAR mRNA in MCF7 cells. E) The effect of TIGAR 
and scrambled siRNA on TIGAR protein in MCF7 cells. F) Knockdown of TIGAR increases the potency 
of 8PC6 by 2-fold in MCF7 cells. 
 
We next sought to determine the mechanism of cell death induced by 8PC6. Flow 
cytometry was used to assess annexin V and 7-aminoactinomycin D staining in cells 
treated with increasing doses of 8PC6 (25 nM–2.5 µM) for 24 hours (Figure 2A and 
Supplementary Figure 27). In cells treated with <1 µM 8PC6 we observed a dose-
dependent increase in cells undergoing the earlier stages of apoptosis, accompanied 
by a reduction in cell viability, and a small percentage of late apoptotic and/or necrotic 
cells (Figure 2A). At doses higher than 1µM of 8PC6, we observed a much greater 
proportion of cells in the latter stages of apoptosis, accompanied by a reduction in the 
number of cells expressing phosphotidylserine and very low levels of total cell viability 
(Figure 2A). The observed pattern of annexin V/7-AAD staining for 8PC6 is indicative 
of cell death via apoptosis and agrees with previously reported data for cribrostatin 6 
(16). 
The effect of 8PC6 on intracellular ROS levels was next probed using the ROS-sensing 
dye 2’,7’-dichlorofluorescin diacetate (DCFDA) (3, 23). No fluorescence was observed 
at 529 nm in MCF7 cells treated with 100 µM DCFDA alone (Figure 2B, upper panel), 
whereas a significant increase in 529 nm fluorescence was observed when cells were 
treated with 2.5 µM 8PC6 prior to the addition of 100 µM DCFDA (Figure 2B, lower 
panel). Quantification of this change in fluorescence showed a dose-dependent 
increase in fluorescence with increasing doses of 8PC6 (Figure 2C), indicating that 
treatment with 8PC6 results in an increase in intracellular ROS. 
These data suggest that 8PC6 selectively targets cancer cells, presumably as a result 
of their increased ROS content. Consequently, we next sought to establish a link 
between variations in intracellular ROS and the effect of 8PC6 on cell viability in the 
same cell line. To increase intracellular ROS we utilized TIGAR, a P53-inducible protein 
that regulates glycolysis and apoptosis and serves to protect cells from ROS. 
Knockdown of TIGAR has been shown to result in an increase in intracellular ROS (24), 
therefore the effect of 8PC6 would be expected to be more pronounced in cells treated 
with TIGAR siRNA. MCF7 cells treated with 50 nM TIGAR siRNA showed the expected 
knockdown in TIGAR mRNA and protein levels, while 50 nM of scrambled control 
siRNA had no effect on TIGAR mRNA or protein levels (Figure 2D and 2E). In line with 
our hypothesis, 1 µM of 8PC6 reduced the viability of MCF7 cells with TIGAR knocked-
down by over 90%, a 2-fold increase in potency compared to the effect of the same 
dose of 8PC6 in untreated MCF7 cells and/or MCF7 cells treated with scrambled siRNA 
(Figure 2F). The effect of TIGAR knockdown on the IC50 of 8PC6 was further quantified; 
the IC50 of 8PC6 was 478 ± 76 nM in untreated MCF7 cells and 477 ± 150 nM in MCF7 
cells treated with scrambled siRNA, whereas the potency of 8PC6 was increased by 
1.5-fold, with an IC50 of 326 ± 19 nM, in MCF7 cells treated with TIGAR siRNA 
(Supplementary Figure 28-30).  
To assess the effect of 8PC6 in MCF7 cells with reduced intracellular ROS we utilized 
N-acetylcysteine (NAC), a molecule that not only functions as a ROS-scavenger, but 
also acts as the precursor to glutathione (another ROS-scavenging molecule) (25). 
NAC-treatment has previously been shown to protect cells from the oxidative damage 
of other ROS-generating molecules (11), and would therefore be expected to reduce 
the effect of 8PC6 on cancer cell viability. The protective effect of NAC was apparent 
when comparing micrographs of MCF7 cells pre-treated with NAC prior to 
administration of 8PC6, to those treated with 8PC6 only (Figure 3A). The observed 
protective effect of NAC on 8PC6-treated cells was quantified by MTT assay; pre-
treatment of MCF7 cells with 5mM NAC resulted in a 20-fold loss in the potency of 
8PC6, with the IC50 of 8PC6 increasing to 9086 ± 95 nM in these cells (Figure 3B). The 
above data demonstrates that the activity and potency of 8PC6 directly correlates with 
intracellular ROS levels.  
The mechanism of action of 8PC6 was next probed. The generation of superoxide by 
quinones requires molecular oxygen (8), and as 8PC6 is proposed to function through 
a similar mechanism, its potency is expected to be reduced in cells pre-incubated in a 
hypoxic environment. It should be noted that while hypoxia leads to a short-term 
increase in basal ROS in cells (6, 26), the decrease in molecular oxygen levels within 
these cells means that ROS generation by 8PC6 and its subsequent effect on cell 
viability would be expected to be reduced.  
MCF7 cells were pre-incubated in hypoxia for 24 hours, treated with increasing doses 
of 8PC6 in hypoxia, and the effect on cell viability measured by MTT assay after a 
further 24h of incubation in a hypoxic environment. In line with our hypothesis, the IC50 
of 8PC6 was significantly raised in hypoxic MCF7 cells to 19.6 ± 7 µM (Figure 3C). To 
further demonstrate the link between the observed loss of 8PC6 potency in hypoxia 
and the reduction in molecular oxygen, MCF7 cells were pre-incubated in hypoxia, 
treated with 8PC6 and then switched to a normoxic environment for 24 h prior to 
assessing their viability by MTT assay. The IC50 of 8PC6 was measured as 1.47 ± 0.1 
µM in these cells. This increase in the potency of 8PC6 (compared to cells treated and 
incubated in hypoxia only) demonstrates the necessity of molecular oxygen for the 
activity of this 8PC6.  
The effect of 8PC6 on the long-term proliferative potential of cancer cells was probed 
using a colony forming assay. MCF7 cells were treated with a single dose of 8PC6 (0.5 
µM, 1 µM, 1.5 µM, 2 µM) and incubated for 10 days to assess their colony forming 
potential. We observed a dose-dependent reduction in the number and size of colonies 
formed in cells treated with 8PC6 compared to untreated cells (Figure 3D and 
Supplementary Figure 30), with a 2 µM dose of 8PC6 causing a 2.7-fold reduction in 
the clonogenicity of MCF7 cells (Supplementary Figure 31). 
 
 
Figure 3. Probing the role of 8PC6 in MCF7 cells. A) Micrographs of MCF7 cells treated with 
increasing doses of 8PC6 (top row) and MCF7 cells treated with 5 mM NAC prior to dosing with 8PC6 
(bottom row). B) The effect of 5 mM of NAC on the potency of 8PC6 in MCF7 cells. C) The effect of a 
hypoxic microenvironment of the potency of 8PC6. D) The effect of increasing doses of 8PC6 on the 
clonogenic survival of MCF7 cells (quantified in Supplementary Figure 31). 
 
Conclusions 
Our findings demonstrate that 8PC6 and cribrostatin 6 selectively inhibit the growth of 
cancer cells via elevation of intracellular ROS. Work is currently underway in our 
laboratories to further probe the mechanism and effect of 8PC6 in other cell lines, and 
we are continuing to synthesize and assess additional derivatives of this molecule. 
 
Materials and Methods 
Synthetic chemistry 
Please see supplementary materials and methods for detailed experimental procedures and 
spectroscopic data for all molecules synthesized. 
 
Cell treatments 
Cells were grown in the presence or absence of test compounds for 24 hours unless stated 
otherwise. For all compounds, serially diluted stock solutions were made up in DMSO and 
then further diluted such that the final concentration of DMSO in each well was 0.5% v/v. For 
treatment with N-acetylcysteine (NAC), an aqueous solution of NAC was added to cells for 1 
h prior to addition of 8PC6, with a final concentration of NAC of 5 mM. For experiments 
involving the culture of cells under hypoxic conditions, cells were initially cultured and 
seeded under normoxic conditions, and then transferred to a hypoxia workstation (H35 
Hypoxystation, Don Whitley) and either pre-incubated for 24 h in hypoxic conditions (1% 
oxygen, 5% carbon dioxide, 37oC) and then dosed and incubated with 8PC6 in normoxic 
conditions for 24 h; or grown continuously in hypoxic conditions, including 24 h of pre-
incubation and 24 h of treatment with 8PC6. 
 
MTT cell viability assays 
Cells were seeded in triplicate in 96-well plates at optimized cell densities appropriate to the 
size and doubling times of the various cell lines used in the study to produce equivalent cell 
confluency prior to experiments (MCF-7 8000 cells / well; HeLa 6000 cells / well; PANC-1 
10,000 cells / well; MDA-MB-231 12,000 cells / well; HCT116 20,000 cells / well; MRC5 
6000 cells / well; and CCD841 7000 cells / well). Cells were incubated for 16 hours prior to 
dosing with test compounds in fresh medium. MTT-based cell proliferation assays were 
performed 24 hours post-dosing, as follows: culture medium was replaced with fresh culture 
medium without phenol red. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT; Sigma) was freshly prepared in sterile PBS and added to cells at a final concentration 
of 1 mM (10% v/v). Cells were then incubated for up to 4 hours at 37oC until intracellular 
punctate purple precipitates were clearly visible under the microscope. An equal volume of 
DMSO was then added to solubilize the resulting formazan and the cells incubated for 5 
minutes in the dark at room temperature with agitation to further dissolve the insoluble 
formazan particles. Absorbance was measured at 570 nm on a microplate reader (Tecan 
Infinite M200 Pro) and corrected for 650 nm background. Each well was triplicated and each 
experiment repeated at least three times. IC50 values quoted are mean ± SEM. 
 
Detection of ROS species using DCF-DA fluorophore 
MCF-7 cells were either seeded in duplicate at 20,000 MCF-7 cells per well in collagen-
coated 8-well NUNC LabTek 2 chamber slides for fluorescent microscopy or seeded in 
triplicate at 10,000 MCF-7 cells per well in a black 96-well plate for quantitative fluorescent 
assays. In both cases cells were then incubated for 16 hours in cell culture media without 
phenol red prior to any treatments. Culture media was gently removed, and the cells washed 
in warm PBS. Warm PBS containing dichlorodihydrofluorescein diacetate (DCF-DA, Sigma) 
was added to the cells to give a final concentration of 100 µM, and the cells were incubated 
for 30min with the dye. The PBS containing DCF-DA was then gently removed, and replaced 
with fresh cell culture media without phenol red. Cells were then dosed with 8PC6 and 
incubated for 6 hours. For the fluorescent microscopy experiments, cells on chamber slides 
were imaged using a fluorescent microscope (Ex 495nm / Em 529nm) and the experiment 
was repeated three times with representative micrographs shown. For quantitative analyses 
of DCF-DA fluorescence, cells on black 96-well plates were then washed in PBS and 
resuspended in a final volume of 80 µL fresh PBS. Fluorescence was measured at Ex 
495nm / Em 529nm using a microplate reader (Tecan Infinite M200 Pro) and background 
fluorescence levels consisting of blank wells containing only DCF-DA in PBS subtracted. 
These experiments were repeated three times and data expressed as mean fold-change ± 
SEM. 
 
siRNA transfection  
MCF-7 cells were seeded at either 7000 cells / well on 96-well plates for MTT assays, 
250,000 cells / well on 6-well plates for harvesting RNA for qPCR analysis, or 1,000,000 
cells / 6cm dish for harvesting protein for performing immunoblotting. Cells were incubated 
for 16h following seeding. Cell densities were optimized so that cells reached 50-70% 
confluency just prior to transfection with siRNA. All cells were transfected with siRNA using 
Lipofectamine RNAiMax transfection reagent (Life Technologies) according to the 
manufacturer’s instructions for performing a ‘forward transfection’. Briefly, cell culture media 
was removed from cells prior to transfection and replaced with serum-free OptiMEM (Life 
technologies) cell culture medium. siRNA was firstly diluted in a small volume of OptiMEM 
equivalent to 10% of the final volume of cells and incubated at RT for 5 min. In parallel, 
Lipofectamine was diluted in a small volume OptiMEM equivalent to 10% of the final volume 
of cells and incubated at RT for 5 min. The diluted oligonucleotides and Lipofectamine were 
then combined and mixed gently, and then incubated at RT for 10min. The siRNA-
Lipofectamine complexes formed were added to cells, which were incubated at 37oC for 24 
h. The final concentration of siRNA was 50nM and the final amount of Lipofectamine was 
0.2% v/v for all experiments. Cells were either transfected with TIGAR siRNA (Silencer 
Select pre-designed annealed human oligonucleotide duplex; s32680; Life Technologies), 
scrambled siRNA (Silencer Select negative control number 2; Life Technologies) or vehicle 
alone. Following transfection, cells were either harvested for total RNA extraction (as 
above); harvested for whole protein extraction (as above); or fresh culture media was added 
and cells were dosed with 8PC6 for 24 h and then an MTT assay performed (as above). 
 
Quantitative RT-PCR 
Total RNA was extracted from MCF-7 cells transfected with either TIGAR siRNA or 
scrambled siRNA using RNeasy Mini Kit (QIAGEN) and quantified using a Nanodrop ND-
1000 spectrophotometer. Complementary DNA was synthesised in a 20 μl reaction 
containing 1 μg of total RNA, using iScript™ cDNA synthesis kit (Bio-Rad) according to the 
manufacturer's instructions. Quantitative real-time PCRs were performed using Universal 
Taqman PCR master mix (Applied Biosystems) and the TIGAR (C12orf15; 
Hs00608644_m1) Taqman Gene Expression Assay (Applied Biosystems) on a CFX 
Connect Real-Time PCR system (Bio-Rad). Fold change for each experiment was 
calculated and normalized using the geometric mean of the expression of 18S and Beta-
actin. Mean values for fold change ± SEM are given. 
 
Protein immunoblotting 
Cells were washed with ice-cold PBS and harvested on ice. Cells were lysed by incubation 
on ice for 15 min with radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.4], 
150 mM NaCl, 10% [v/v] sodium-deoxycholate, 10% [v/v] IGEPAL CA-630; Sigma) 
containing protease inhibitor cocktail. Lysates were sonicated for 1 min in a sonicating water 
bath and then centrifuged at 10,500 rpm for 10 min at 4oC. The protein concentration in the 
supernatant was quantified by the Bradford assay. Proteins were separated on SDS-
polyacrylamide Bis-Tris gels under denaturing conditions, transferred to unsupported pure 
nitrocellulose membrane (Amersham), and subjected to immunoblot analysis.  
A mouse monoclonal primary antibody raised against TIGAR (9C10; 1:100; Santa Cruz) was 
used for blotting. Antibodies were diluted in phosphate-buffered saline containing 5% non-fat 
powdered milk and 0.1% Tween 20, and incubated with the membrane overnight at 4oC. 
Horseradish peroxidase-conjugated anti-mouse immunoglobulin G antibody (NXA931, 
1:4000; GE Healthcare) was used as the secondary antibody, and monoclonal anti-b-actin-
peroxidase antibody (A3854, 1:50,000; Sigma) served as a loading control. Bound 
immunocomplexes were detected using ECL prime western blot detection reagent 
(RPN2232; GE Healthcare) and analyzed using Image Lab 4.0 computer software (Bio-
Rad). Experiments were repeated three times and a representative blot shown. 
 
Apoptosis assay 
MCF-7 cells were seeded at 8 × 104 cells/well on 12-well plates and incubated for 16 hours 
prior to being dosed with different concentrations of 8PC6, as described above. Cells were 
harvested after 24 hours of drug exposure. This was performed by firstly removing the 
culture media from the treated cells, which was set aside and later pooled back together with 
the treated cells, in order to retain any dead, apoptotic and detached cells contained in the 
spent culture media. Then all remaining adherent cells were gently detached from plates 
using StemPro Accutase cell dissociation solution (Life Technologies), which helps maintain 
plasma membrane integrity, and therefore phosphatidylserine (PS) expression. Cells were 
stained with 7-amino-actinomycin (7-AAD) and FITC-annexin V, using a commercially 
available FITC-Annexin V Apoptosis Detection Kit (Biolegend, #640922) according to the 
manufacturer’s instructions, with some cell line-specific optimization. Briefly, 7-AAD and 
FITC-annexin V was diluted in binding buffer at a ratio of 1 in 25 and 1 in 400, respectively, 
and then added to cell suspensions at a ratio of 1:1. Cells were incubated for 15 minutes at 
room temperature in the dark with gentle agitation. The stained cells were then analyzed by 
flow cytometry on an ACEA Novocyte 1000 (ACEA Biosciences Inc.). Percentage of early 
apoptotic and late apoptotic/necrotic cell populations were calculated using NovoExpress 
software (version 1.2.1, ACEA Biosciences Inc.) and compared with appropriate controls. 
 
Colony forming assays 
MCF-7 cells were seeded in duplicate at 800 cells per dish in 6-cm dishes 16 hr prior to 
dosing with 8PC6 for 24 hr. Cells were then gently washed in PBS and fresh culture medium 
added. Cells were cultured for up to 14 days until colonies were visible with fresh medium 
added every 48–72 hr. At the end of the experiment cells were fixed by addition of 
methanol/acetic acid (3:1) for 5 min, then stained in 0.5% (v/v) crystal violet solution (diluted 
in methanol) for 10 min, and colonies counted using the colony area plugin for imageJ. The 
experiments repeated twice and representative images are shown. 
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